December

Gome Fin Tech Announced Annual Results of 2023

Source Node:
Time Stamp: April 1, 2024 1:23 PM - Modified On: April 1, 2024 - Published By:
Source Cluster:
Republished By Plato

  Commercial Factoring Progresses Despite Stability Diversified Businesses Ready for Development HONG KONG, Mar 29, 2024 - (ACN Newswire) - Gome Finance Technology Co., Ltd.(Stock Code:628.HK,“Gome Fin Tech”or “the Company”,with its subsidiaries,the“Group”), announced its audited annual results for the year ended 31 December, 2023 (the “Reporting Period”). In 2023, the global geopolitical risks are frequent, the lack of economic recovery momentum and the widening trend of differentiation among countries are highlighted, and the risk spillover from European and US banks under the global high interest rate environment also casts a

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Reasons for Regulation

Source Node:
Time Stamp: January 5, 2023 3:57 AM - Modified On: January 5, 2023 - Published By:
Source Cluster:
Republished By Plato

There are multiple reasons cited for increased regulation in crypto, the most common of which are investor protection, institutional adoption, and safety. While regulations can be seen as a good thing in general for the space they’re by no means a universal panacea. Examining what central banks want regulation to look like gives a clearer indication of who benefits most from them. In December Sir Jon Cunliffe, Deputy Governor of the Bank of England said, “We would need to regulate to ensure that we get the same level of protection,

Paribus. After the storm.

Source Node:
Time Stamp: December 21, 2022 2:39 AM - Modified On: December 21, 2022 - Published By:
Source Cluster:
Republished By Plato

If the global financial system is an ocean and the ships on it represent the different markets, crypto would be the equivalent of a small boat tossed around by the storms we’ve experienced this year. Whatever happens with the development of the technology it’s impossible to avoid the effects of global shifts as we saw last week with the Federal Reserve’s latest rate hike. Even though the news from the Fed was exactly what markets had anticipated and priced in, the response was turbulent which caused more moves to the

Is the Future Digital?

Source Node:
Time Stamp: December 8, 2022 4:16 AM - Modified On: December 8, 2022 - Published By:
Source Cluster:
Republished By Plato

These days you can’t scroll through YouTube without encountering videos foretelling the end of crypto and the collapse of the global financial system. The clickbait culture that invaded traditional journalism has now spread to citizen journalism too, but how realistic are all of these dramatic claims? Fear, uncertainty, and doubt (FUD) pervade the mainstream media. So much so that even people with little knowledge of the technology claim it’s all going to zero. If you’re looking for bottom signals this is the equivalent of everyone FOMOing in at the top.